LYON, France, Sept. 22, 2014 (GLOBE NEWSWIRE) -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, announced that the growing interest in and acceptance of its Ablatherm®-HIFU technology was once again highlighted as a valuable treatment alternative for prostate cancer patients in a presentation at the World Congress of Endourology (WCE) in Taipei, Taiwan from September 3-7, 2014.

The use of High Intensity Focused Ultrasound (HIFU) technology in the treatment of prostate cancer was featured in a plenary session of the conference, moderated by long term Ablatherm-HIFU user, Dr. Christian Chaussy, Professor of Urology, University of Munich, Germany. Posters on the use of Ablatherm-HIFU highlighted the importance of imaging technologies to more effectively locate prostate cancer, enabling improvements in treatment efficacy and reductions in retreatment rates. Also presented were highly positive clinical results at 5 and 10 years, following HIFU treatment of advanced prostate cancer patients. These outstanding results provide advanced prostate cancer patients a clear and viable therapeutic alternative, avoiding or postponing hormonal treatments and their dramatic side effects.

Marc Oczachowski, EDAP's Chief Executive Officer, commented, "It is a well-deserved validation of Ablatherm HIFU to have it highlighted in such a prestigious international conference that is attended by urologists from around the world. Interest in HIFU in the treatment of prostate cancer is growing worldwide and EDAP, with its Ablatherm®-HIFU and Focal One® devices for the treatment of localized prostate cancer, is well positioned to address this highly prevalent global medical need."

About EDAP TMS SA

EDAP TMS SA markets today Ablatherm^® for high-intensity focused ultrasound (HIFU) treatment of localized prostate cancer. HIFU treatment is shown to be a minimally invasive and effective treatment option with a low occurrence of side effects. Ablatherm-HIFU is generally recommended for patients with localized prostate cancer (stages T1-T2) who are not candidates for surgery or who prefer an alternative option, or for patients who failed radiotherapy treatment. Ablatherm-HIFU is approved and commercialized in Europe as a treatment for prostate cancer and is currently under regulatory review in the U.S. following submission of the Pre-Market Approval Application in February 2013 after the completion of a multi-center U.S. Phase II/III clinical trial under an Investigational Device Exemption (IDE) granted by the FDA. In February 2014, the Company introduced a new innovative HIFU device, the Focal One^® dedicated to focal therapy of prostate cancer. Focal One^® is CE marked but is not FDA approved. The Company also develops its HIFU technology for the potential treatment of certain other types of tumors. EDAP TMS SA also produces and commercializes medical equipment (the Sonolith^® range) for treatment of urinary tract stones using extra-corporeal shockwave lithotripsy (ESWL). For more information on the Company, please visit http://www.edap-tms.com, and http://www.hifu-planet.com.

Forward-Looking Statements

In addition to historical information, this press release may contain forward-looking statements. Such statements are based on management's current expectations and are subject to a number of risks and uncertainties, including matters not yet known to us or not currently considered material by us, and there can be no assurance that anticipated events will occur or that the objectives set out will actually be achieved. Important factors that could cause actual results to differ materially from the results anticipated in the forward-looking statements include, among others, the uncertainties of the U.S. FDA approval process, the clinical status and market acceptance of our HIFU devices and the continued market potential for our lithotripsy device. Factors that may cause such a difference also may include, but are not limited to, those described in the Company's filings with the Securities and Exchange Commission and in particular, in the sections "Cautionary Statement on Forward-Looking Information" and "Risk Factors" in the Company's Annual Report on Form 20-F. Ablatherm-HIFU treatment is in clinical trials, but not FDA-approved or marketed in the United States.

CONTACT: Blandine Confort

         Investor Relations / Legal Affairs

         EDAP TMS SA

         +33 4 72 15 31 72

         bconfort@edap-tms.com



         Investors:

         Lee Roth / Sam Martin

         The Ruth Group

         646-536-7012 / 7008

         lroth@theruthgroup.com / smartin@theruthgroup.com

News Provided by Acquire Media